Remegen is a company that develops biopharmaceutical products. The company focuses on research and development, manufacturing and commercialization of biologics, notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs), enabling patients and clinicians with pharmaceutical products for the treatment of cancer, autoimmune and eye-related diseases.